Cytori Cell Research Institute, Inc. (3750.T)
JPY 688.0
(1.33%)
JPY 688.0
(1.33%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -603.09 Million JPY | -154.25% |
| 2022 | -705.34 Million JPY | -2629.77% |
| 2021 | 348.9 Million JPY | 104.54% |
| 2020 | -261.85 Million JPY | -888.89% |
| 2019 | 43 Million JPY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | -175.75 Million JPY | 60.36% |
| 2023 Q2 | -215.95 Million JPY | -70.26% |
| 2023 Q1 | -126.83 Million JPY | 42.37% |
| 2023 Q4 | -781.89 Million JPY | -546.99% |
| 2023 Q3 | -120.85 Million JPY | 44.04% |
| 2023 FY | - JPY | -154.25% |
| 2022 Q3 | -53.57 Million JPY | 60.8% |
| 2022 FY | - JPY | -2629.77% |
| 2022 Q4 | -220.09 Million JPY | -310.82% |
| 2022 Q2 | -136.68 Million JPY | 0.0% |
| 2021 FY | - JPY | 104.54% |
| 2020 FY | - JPY | -888.89% |
| 2019 FY | - JPY | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 958.1 Million JPY | 162.946% |
| PRISM BioLab Co.,LTD | -488.13 Million JPY | -23.551% |
| GNI Group Ltd. | 14.48 Billion JPY | 104.162% |
| Linical Co., Ltd. | 1.24 Billion JPY | 148.354% |
| Trans Genic Inc. | 240.95 Million JPY | 350.295% |
| MEDINET Co., Ltd. | -1.35 Billion JPY | 55.52% |
| Soiken Holdings Inc. | -583.2 Million JPY | -3.41% |
| AnGes, Inc. | -8.86 Billion JPY | 93.193% |
| OncoTherapy Science, Inc. | -1.28 Billion JPY | 53.085% |
| Nxera Pharma Co., Ltd. | -7.39 Billion JPY | 91.849% |
| Immuno-Biological Laboratories Co., Ltd. | 128.1 Million JPY | 570.771% |
| NanoCarrier Co., Ltd. | -863 Million JPY | 30.117% |
| Carna Biosciences, Inc. | -1.09 Billion JPY | 44.761% |
| CanBas Co., Ltd. | 53.65 Million JPY | 1224.1% |
| D. Western Therapeutics Institute, Inc. | -775.59 Million JPY | 22.241% |
| RaQualia Pharma Inc. | -111.8 Million JPY | -439.433% |
| Chiome Bioscience Inc. | -1.21 Billion JPY | 50.229% |
| Kidswell Bio Corporation | -1.38 Billion JPY | 56.324% |
| PeptiDream Inc. | 7.37 Billion JPY | 108.176% |
| Oncolys BioPharma Inc. | -1.92 Billion JPY | 68.747% |
| Ribomic Inc. | -1.01 Billion JPY | 40.437% |
| SanBio Company Limited | -4.52 Billion JPY | 86.672% |
| Healios K.K. | -3 Billion JPY | 79.944% |
| BrightPath Biotherapeutics Co., Ltd. | -1.16 Billion JPY | 48.267% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -1.39 Billion JPY | 56.708% |
| Delta-Fly Pharma, Inc. | -1.4 Billion JPY | 56.984% |
| StemRIM | -2.03 Billion JPY | 70.32% |
| CellSource Co., Ltd. | 1.3 Billion JPY | 146.163% |
| FunPep Company Limited | -952 Million JPY | 36.65% |
| Kringle Pharma, Inc. | -888.76 Million JPY | 32.143% |
| Stella Pharma Corporation | -723.85 Million JPY | 16.683% |
| TMS Co., Ltd. | -937 Million JPY | 35.636% |
| Noile-Immune Biotech Inc. | -775.39 Million JPY | 22.221% |
| Cuorips Inc. | -518 Million JPY | -16.427% |
| K Pharma,Inc. | 366.05 Million JPY | 264.753% |
| Takara Bio Inc. | 8.02 Billion JPY | 107.516% |
| ReproCELL Incorporated | 8.24 Million JPY | 7414.627% |
| PhoenixBio Co., Ltd. | 87.93 Million JPY | 785.814% |
| StemCell Institute Inc. | 534.35 Million JPY | 212.864% |
| Japan Tissue Engineering Co., Ltd. | 244.81 Million JPY | 346.347% |
| CellSeed Inc. | -836.51 Million JPY | 27.904% |